Display options
Share it on

Materials (Basel). 2021 May 30;14(11). doi: 10.3390/ma14112958.

Characterization of Metal-Bound Benzimidazole Derivatives, Effects on Tumor Cells of Lung Cancer.

Materials (Basel, Switzerland)

Anita Raducka, Agnieszka Czylkowska, Katarzyna Gobis, Kamila Czarnecka, Paweł Szymański, Marcin Świątkowski

Affiliations

  1. Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland.
  2. Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gen. Hallera 107, 80-416 Gdansk, Poland.
  3. Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
  4. Department of Radiobiology and Radiation Protection, Military Institute of Hygiene and Epidemiology, 4 Kozielska St., 01-163 Warsaw, Poland.

PMID: 34070886 PMCID: PMC8198142 DOI: 10.3390/ma14112958

Abstract

Four new ligands and four new copper (II) coordination compounds were prepared and characterized by chemical, elemental analysis, cytotoxicity, and FTIR spectroscopy (Fourier transform infrared spectroscopy). The nature of metal-ligand coordination was investigated. The thermal properties of complexes in the solid state were studied using TG-MS techniques (thermogravimetric analysis coupled with mass spectrometry) under dynamic flowing air atmosphere to analyze the principal volatile thermal decomposition and fragmentation products that evolved during thermolysis. The intermediate and final solid thermolysis products were also determined. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay was used to evaluate active metabolic cells as an IC

Keywords: benzimidazole derivatives; copper (II) coordination compounds; lung cancer; thermogravimetric analysis

References

  1. EMBO Mol Med. 2021 Jan 11;13(1):e13122 - PubMed
  2. Eur J Med Chem. 2020 Dec 1;207:112745 - PubMed
  3. Lancet Haematol. 2020 Apr;7(4):e351-e352 - PubMed
  4. Bull Cancer. 2020 Jun;107(6):629-632 - PubMed
  5. Crit Rev Oncol Hematol. 2021 Jan;157:103189 - PubMed
  6. Mol Cell Biochem. 2019 Oct;460(1-2):123-150 - PubMed
  7. Exp Toxicol Pathol. 2003 Mar;54(4):339-47 - PubMed
  8. Bone Marrow Transplant. 2021 Jan;56(1):267-269 - PubMed
  9. J Mol Struct. 2021 Jan 15;1224:129026 - PubMed
  10. Lung Cancer. 2021 Feb;152:49-57 - PubMed
  11. J Gastrointest Surg. 2020 Oct;24(10):2357-2373 - PubMed
  12. Int J Mol Sci. 2020 May 31;21(11): - PubMed
  13. Int J Cancer. 2021 Feb 1;148(3):626-636 - PubMed
  14. Haematologica. 2020 Jul 30;105(12):2872-2878 - PubMed
  15. Int J Lab Hematol. 2020 Dec;42(6):e256-e259 - PubMed
  16. JCO Glob Oncol. 2020 May;6:722-729 - PubMed
  17. Curr Med Chem. 2021 Feb 19;: - PubMed
  18. Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26190-26196 - PubMed
  19. Eur J Haematol. 2020 Nov;105(5):597-607 - PubMed
  20. Cancer Treat Res Commun. 2021;26:100285 - PubMed
  21. Pharmacol Res. 2020 Aug;158:104850 - PubMed
  22. J Neurochem. 2009 Nov;111(3):656-68 - PubMed
  23. Comput Biol Med. 2021 Mar;130:104186 - PubMed
  24. Bioorg Chem. 2020 Sep;102:104125 - PubMed
  25. J Surg Oncol. 2021 Jan;123(1):12-23 - PubMed
  26. Curr Oncol Rep. 2020 May 8;22(5):53 - PubMed
  27. Thorac Cancer. 2021 Jan;12(1):57-65 - PubMed
  28. J Med Virol. 2021 Feb;93(2):1099-1104 - PubMed
  29. Blood. 2020 Dec 24;136(26):3033-3040 - PubMed
  30. BMJ Open. 2020 Dec 31;10(12):e041641 - PubMed
  31. JAMA Oncol. 2020 Dec 1;6(12):1881-1889 - PubMed
  32. BMJ. 2020 Feb 28;368:m810 - PubMed
  33. Methods Mol Med. 2004;88:159-64 - PubMed
  34. Pharmacol Res. 2020 Jul;157:104859 - PubMed
  35. Clin Colorectal Cancer. 2020 Sep;19(3):156-164 - PubMed
  36. Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43 - PubMed
  37. Lancet Oncol. 2021 Jan;22(1):66-73 - PubMed
  38. Lancet Infect Dis. 2020 Nov;20(11):1240-1241 - PubMed

Publication Types